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Angiotensin-Converting Enzyme:
I. New Strategies for Assay
by James W. Ryan,* Alfred Chung,* and Una S. Ryan*
Thedispositionofconvertingenzyme(kininaseH)ontheluminalsurfaceofpulmonaryendothelialcellsis
well established. Further, it is known that there is a net conversion ofangiotensin I into angiotensin H as
blood passes through the lungs. However, little is known about modulations ofconverting enzyme activity
that may arise through, e.g., changes in the quality ofinhalants, blood flow, or blood oxygenation. There
are few data on the effects of lung disease. A major barrier to studies to examine for pathophysiologic
modulations ofconverting enzyme is that of assay. The enzyme can be measured in terms of the rate of
formationofangiotensin Hfromaknownquantity ofangiotensinI. However, bothpeptidesarebiologically
active, and lungs contain other enzymes capable of degrading them. We have developed a series of
radiolabeled, acylated tripeptides to improve our ability to examine for changes in the net converting
enzyme of intact lungs. The enzyme, a dipeptidyl carboxypeptidase, is capable of removing C-terminal
dipeptides from a variety ofoligopeptides. We have prepared benzoyl-Gly-Gly-Gly (I), benzoyl-Pro-Phe-
Arg (H), benzoyl-Gly-His-Leu (HI), benzoyl-Phe-Ala-Pro (IV), and benzoyl-Phe-His-Leu (V), each con-
taininga 3H-atom inthepara positionofthebenzoylmoiety. Substrates IandHI havebeenusedpreviously
in photometric assays of low sensitivity. H is the acylated C-terminal tripeptide of bradykinin, IV is an
acylatedtripeptide analogofBPP5a (<Glu-Lys-Trp-Ala-Pro) andVistheacylated C-terminal tripeptideof
angiotensin I. Thesesubstratescanbeusedinvitro orinvwiotomeasureconvertingenzyme. The3H-labeled
productisseparablebypartitioningbetweenanorganicsolventandacidifiedaqueoussolution. Theproduct
is quantified by scintillation countingofthe organic phase. Thechoice ofsubstrate depends on the goals of
the experiment: substrate I or HI when wide variations in substrate concentrations are needed but high
sensitivity is not; substrate IV when high sensitivity is needed.
Introduction
Angiotensin-converting enzyme appears to occur
in association with endothelial cells of virtually all
vascularbeds (1). The enzyme also occurs in associ-
ation with brush border of renal proximal tubule
(2, 3) and small intestine (4). However, bulk conver-
sion of angiotensin I into angiotensin II occurs,
apparently unaided by blood enzymes, within the
pulmonary vascular space. Angiotensin-converting
enzyme is situated on the luminal surface ofpulmo-
nary endothelial cells (5-8) and is strategically placed
forbulkprocessing, notonlyofangiotensin I butalso
bradykinin and perhaps other oligopeptides (neuro-
tensin, enkephalins) having adequate affinity for the
enzyme. The lungs have an enormous vascular bed
through which flows the entire cardiac output.
Further, because of the peculiar situation of the
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lungs within the general circulation, their venous
effluentempties directly intothe arterial circulation.
Hence, the activity or inactivity oflung angiotensin
converting enzyme may mattergreatly tothe quality
ofarterialbloodandtothefunction ofdistantorgans.
Whether angiotensin-converting enzyme is impor-
tant to intrinsic lung function remains to be deter-
mined.
A major barrier to improved understanding ofthe
pathophysiologic roleoflungangiotensin-converting
enzyme is that of adequate techniques for assay. In
principle, one should be able to measure modula-
tions ofenzyme activity by examining for variations
in the pulmonary arteriovenous gradients of an-
giotensin I, angiotensin II, and bradykinin. How-
ever, these substances occur in blood at concentra-
tions of less than 10-0°M. Radioimmunoassays can
be used, but the precision ofsuch assays is not great
and their specificities, especially forbradykinin, are
not proved. The assay problem is not substantially
improved by following the changes of activity of
April 1980 165intravenously administered bradykinin or angioten-
sin I, either by radioimmunoassay or the dynamic,
on-line bioassay system of Vane (9). Furthermore,
the bioassay is not readily adaptable for use with
human subjects.
In an effort to develop simpler and more precise
meansofmeasuringangiotensin-converting enzyme,
we have synthesized a series ofacylated tripeptides,
each bearing a radioisotope in the moiety used for
acylation. Most have been prepared to contain a
3H-atom, but y-emitting isotopes, e.g., 1251, can be
used as well. Angiotensin-converting enzyme func-
tions as a dipeptidyl carboxypeptidase and acts on
acylated tripeptides to yield adipeptide and an acyl-
amino acid (10, 11). By careful selection of amino
acid residues one can vary the affinity of substrate
for enzyme. As has been shown for benzoyl-Gly-
His-Leu (hippuryl-His-Leu) (12, 13), the acyl-amino
acid product can be separated from the acyl-
tripeptide substrate by partitioning between acid-
aqueous solvent and anorganic solvent suchasethyl
acetate or toluene. The efficiency of the extraction
technique is a function of amino acid residues and
their sequence. Thus an aromatic or aliphatic amino
acid is advantageous for the 3H-labeled product and
a basic amino acid is useful when placed in the di-
peptide leaving group.
Six radiolabeled acylated tripeptides have been
prepared, and four have been characterized in detail
as substrates for angiotensin converting enzyme.
Three of the latter compounds can be used to mea-
sure converting enzymes of lungs perfused with
artificial salt solutions. We believe that these three
substrates can be used to measure lung converting
enzyme in vivo.
Materials and Methods
Synthetic bradykinin and its higherhomologs, an-
giotensin I and its lowerhomologs, andBPPiaand its
lower homologs were prepared by the solid-phase
peptide synthesis technique (14). The completed
peptides were purified by two or more ofthe follow-
ing techniques: counter-current distribution,
molecular sieve chromatography (Bio-Gel P-2,
Sephadex G-25), and partition chromatography
(LH-20 within 6% butanol in H20; Sephadex G-25
with butanol, acetic acid, H20; 4:1:5). The peptides
were synthesized by J. M. Stewart, University of
Colorado Medical Center and G. H. Fisher, Univer-
sity of Miami (15).
The compounds, p-I-benzoyl-Gly-Gly-Gly, p-I-
benzoyl-Pro-Phe-Arg, p-I-benzoyl-Gly-His-Leu,
p-I-benzoyl-Phe-Ala-Pro,p-I-benzoyl-Phe-His-Leu,
and p-I-benzoyl-Phe-Ser-Pro, were synthesized by
stepwise solution methods (16, 17). Purifications
were accomplished with one or more of the follow-
ing techniques: molecular sieve chromatography
(Sephadex G-10), ion-exchange chromatography
(CM-SephadexorDEAE-Sephadexwithammonium
acetate buffers). Thep-3H-benzoyl derivatives were
prepared by New England Nuclear Corp. by de-
halogenation in 3H2 gas at 39 psi for 1 hr over 5%
rhodium on calcium carbonate in dimethylfor-
mamide and H20, 1:1 (vlv). Each of the 3H-labeled
acyl-tripeptides was obtained at specific radio-
activities of >20 Ci/mmole. The 3H-labeled com-
pounds were purified on Sephadex G-10, and each
behaved as a pure substance in two or more thin-
layer chromatography systems (16) and on paper
electrophoresis at pH 2.0 and 5.0 (18). The 3H-
labeled compounds, stored at 1 mCi/ml ofethanol at
-28°C, did not undergo detectable radiolysis over a
period of 12 months.
Our studies used angiotensin-converting enzyme
partially-purified from guinea pig lung or urine and
human urine (17). Pure rabbit lung angiotensin con-
verting enzyme was provided by R. L. Soffer, Cor-
nell University Medical College (11).
The experiments using anesthetized rats or per-
fused isolated rat lung were performed as described
byRobleroetal. (19)andRyanetal. (20). Forin vitro
assays, weused the protocol describedbyRyanetal.
(16). Inbrief, reactions were stopped by adding0.IN
HCI to a pH <2. The H-labeled acyl-amino acid
product was extracted into an equal volume of
organic solvent. Ethyl acetate was used for all sub-
strates except 3H-benzoyl-Phe-Ala-Pro. Toluene
was used for extraction of reaction mixtures con-
taining the latter substrate (17).
Results and Discussion
Recognition Sites of Angiotensin-Converting
Enzyme
In the early 1970's, it was recognized that
angiotensin-converting enzyme is misnamed. The
enzyme acts as a dipeptidyl carboxypeptidase capa-
ble ofremoving the C-terminal dipeptide ofa variety
ofoligopeptides (10, 21, 22). In fact, bradykinin is a
better substrate (lowerK.) thanis angiotensin I, and
the enzyme is sometimes known as kininase II. In
terms ofK., the venom peptide, BPP5a (23) is the
best of the known substrates (K. <10-6M).
Clearly, the enzyme is not specific, but there is
reason to believe that the enzyme is highly selective.
Further, it is evident that the enzyme possesses a
number of recognition sites; knowledge of which is
useful for design of synthetic substrates.
In ourearly studies on the metabolism ofkinins by
intact lungs, we noted that bradykinin is inactivated
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homologs (19, 24). When pure lung angiotensin con-
verting enzyme became available (25), it was found
that much ofthe selectivity ofprocessingofkinins by
intact lungs could be explained in terms of one en-
zyme (see Table 1). Clearly, the enzyme is sensitive
to amino acid residues at a distance from the cleav-
age site. Chain length and charge of the substrates
appear to be important factors.
Angiotensin I and its lower homologs are also
treated differently by converting enzyme. As shown
in Table 2, des-Asp1-angiotensin I is a somewhat
bettersubstrate thanis angiotensin I itself(lowerK,
higherVmax/Km). In terms OfVmaxlKm, the C-terminal
pentapeptide is a better substrate thanangiotensin I.
In comparison with some of the acylated tripeptide
substrates to be described below, the C-terminal
hexapeptide is a surprisingly poor substrate. None-
theless, Table 2 emphasizes the points that con-
verting enzyme is sensitive to amino acid residues
distantfrom the cleavage site and that chain length is
an important factor.
Table 1. Processing of bradykinin and its higher homologs by
isolated, perfused rat lungs and by angiotensin-converting
enzyme purified from pig lung.a
Relative reaction rates, %b
Intact Converting
lungs enzyme





Polistes kinin 0 2
aFurther experimental details as described by Dorer et al. (22)
bResults are expressed as relative reaction rates (the rate for
bradykinin = 100o). Rates of hydrolysis by pure enzyme were
measured intermsoftheformationofninhydrin-reactive products
(21). Rates of degradation of kinins by isolated lungs were mea-
sured by bioassay (19, 24).
Greater insight into the importance of enzyme
recognition sites has come from studies of two in-
hibitors of converting enzyme, BPPga (<Glu-Trp-
Pro-Arg-Pro-Gln-Ile-Pro-Pro) and BPP5a (<Glu-
Lys-Trp-Ala-Pro); peptides purified from the venom
ofBothrops jararaca (23, 26). Cushman et al. (27)
have examined for the inhibitory potencies of a
series of analogs of the two inhibitors, and we (15)
have examined for the inhibitory potencies ofBPPga
and its lower homologs. Both studies have shown
that Trp ofBPPga interacts with an important recog-
nition site, apparently distant from the catalytic site
of the enzyme. However, the distant binding site
may not be fixed or stationary, as the N-terminal
homolog of BPPga, <Glu-Trp-Pro-Arg-Pro-Gln-Ile,
and its lowerhomolog, Trp-Pro-Arg-Pro-Gln-Ile, are
virtually as potent as is BPPga itself (respective I50
values: 54, 34, and 28 nM). Results obtained with
some of the homologs are shown in Table 3.
Atpresent, it appearsthatbindingofa substrate or
inhibitor to angiotensin converting enzyme is ini-
tiated by interaction of the free a-carboxy group of
the substrate with an ionic recognition site. Our re-
sults and those of others indicate that the ring of
proline orthe side-chain ofisoleucine aids inbinding
(29, 30). Clearly, the side chains of C-terminal ar-
ginine, as in bradykinin, and leucine, as in angioten-
sin I, are not unfavorable for binding. Similarly,
phenylalanine or histidine are not unfavorable pen-
ultimate residues, but alanine (as in BPP5a) may be
the most favorable. Less attention has been paid so
far to the importance of the side-chain of the third
amino acid residue; i.e., that on the N-terminal side
ofthe cleavage site. Such data as are available indi-
cate that an aromatic amino acid (e.g., Trp ofBPP5a
or Phe of angiotensin I) is favorable for binding.
Judging from the lowI50ofthe C-terminal tripeptide
of BPPga, Ile-Pro-Pro (Table 3), the side chain of
isoleucine fits well. Through such considerations,
we have prepared six acylated tripeptide substrates
for converting enzyme.
Table 2. Reaction of pig lung angiotensin-converting enzyme with angiotensin I
and its C-terniinal lower homologs.a
KM, ALM Vmax Vmax/Km
,umole/min-mg
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu 33 1.98 0.060
Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu 11 0.99 0.090
Val-Tyr-Ile-His-Pro-Phe-His-Leu 170 7.94 0.047
Tyr-Ile-His-Pro-Phe-His-Leu 100 8.83 0.088
Ile-His-Pro-Phe-His-Leu 1000 37.71 0.038
aExperimental details as given previously (28). Reaction rates were measured in terms ofthe appear-
ance ofthe fluorophor formed by reacting His-Leu witho-phthaldialdehyde. Vmaxis expressed in terms
ofjumole/min per mg of enzyme protein.
April 1980 167Table 3. Inhibition of angiotensin-converting enzyme by BPP9a













aData at Fisher et al. (15).
bCompounds were tested fortheirabilitiestoinhibitthe hydrol-
ysis of 3H-hippuryl-His-Leu by human urinary angiotensin-con-
verting enzyme (17).
Design of Synthetic Substrates
We have synthesized the following compounds:
p-I-benzoyl-Gly-Gly-Gly (I), p-I-benzoyl-Pro-Phe-
Arg (II), p-I-benzoyl-Gly-His-Leu (III), p-I-
benzoyl-Phe-Ala-Pro (IV), p-I-benzoyl-Phe-His-
Leu (V), andp-I-benzoyl-Phe-Ser-Pro (VI). Each of
the compounds can be labelled by dehalogenation in
3H2 gas (16, 17). Compounds I-V have been so
labeled and each was obtained at a specific radioac-
tivity of >20 Ci/mmole. Further, each compound
was labeled specifically in position 4 ofthe benzoyl
ring.
Compound I, after tritation, is 3H-hippuryl-Gly-
Gly. Hip-Gly-Gly is commonly used as a substrate
for converting enzyme (31) and appears to be re-
markably resistant to hydrolysis by other enzymes.
However (Table 4), Hip-Gly-Gly has relatively little
affinity forconverting enzyme, and its 3H-derivative
cannot be used to obtain a sensitive assay.
Compound II, the acylated C-terminal tripeptide
of bradykinin, yields a much more sensitive assay,
although its VmaxlKm suggests that one orboth ofthe
products is apoorleaving group. Under some condi-
tions, II is hydrolyzed by acarboxypeptidase B-like
enzyme and is not specific. The encouraging results
obtained with III, Hip-His-Leu, deserves comment,
as the magnitude of its Km is heavily dependent on
selection of buffer and salts. Cushman and Cheung
(12, 13) were the first to use Hip-His-Leu as a sub-
strate for converting enzyme, and undertheircondi-
tions of assay (0.1M phosphate buffer, pH 8.3, plus
0.3M NaCl), Hip-His-Leu has a relatively low affin-
ity for the enzyme (Km>2000 pM). Quite by acci-
dent, wefound thatitsaffinity is greatlyincreasedby
Na2SO4 at 0.75M (17). Phosphate is inhibitory, thus
the most sensitive assay uses 3H-Hip-His-Leu in
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0.05M Hepes buffer, pH 8.0, plus O.1M NaCl and
0.75M Na2SO4. As yet, we have no explanation for
the dramatic effects of S04. Nonetheless, our work
and that of Dorer et al. (31) indicate that it will be
important to check for effects of organ perfusion
solutions (e.g., Krebs-Henseleit solution) on the in-
teractions ofagiven substrate with angiotensin con-
verting enzyme. Plasma and blood are likely to pre-
sent their own problems.
Table 4. Characteristics of the reactions of acylated tripeptides
with angiotensin-converting enzyme.
Vmax,
Substrate ,umole/min Km, jIM Vmax/Km
I benzoyl-Gly-Gly-Gly 75.6 3490 0.022
II benzoyl-Pro-Phe-Arg 4.7 120 0.039
III benzoyl-Gly-His-Leu 18.7 103 0.182
IV benzoyl-Phe-Ala-Pro 3.6 5.4 0.667
V benzoyl-Phe-His-Leu 2.1 5.6 0.375
aEachofthe 3H-labeledsubstrates, withvaryingconcentrations
of unlabeled carrier, was reacted with guinea pig urinary angio-
tensin-converting enzyme such that no more than 10%Wo of initial
substratewasused(17). Similarresultswereobtainedwhenrabbit
lung converting enzyme was used.
Compound IV, an acylated analog of the C-
terminaltripeptide ofBPP5a, canbeused inassays40
times more sensitive than those using Hip-Gly-Gly
(I). Neither II norIVrequiresCl-, and eachisappar-
ently insensitive to added Na2SO4. The Km for IV is
intermediate between that for angiotensin I (33 pM)
and that for bradykinin (0.85 MM) (11, 21, 28).
Concluding Remarks
Depending on the goals of the experiment, com-
pound I, III, orIV, canbeused to measure angioten-
sin converting enzyme of plasma, tissue homoge-
nates, cells in culture, or isolated, perfused lungs.
Compound IVmaywellbe suitableforusewithlungs
of intact animals. Because of the wide range of af-
finities ofthe substrates for converting enzyme and
theirhigh specific radioactivities, it should be possi-
ble to examine for modulations of converting en-
zyme activity using a wide range of substrate con-
centrations. Each of the 3H-labeled substrates,
without carrier, is labeled such that lnM solutions
contain easily detectable radioactivity. Thus the
rangeofconcentrations readilytestedextendsfrom 1
nM to >2Km. So far as is known, none of the sub-
stratesorproductsisbiologicallyactive ortoxic. The
acyl-tripeptides are relatively inexpensive and can
be made in quantity.
Again, according to the goals of a given experi-
ment, an acyl-tripeptide substrate can be selected to
give <10o to >90% hydrolysis during one transit
Environmental Health Perspectivesthrough the lungs. Thus, it should be possible to
define conditions to assess easily effects ofvariables
such as perfusion rate, pressure, toxic inhalants and
oxygenation.
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